Telaprevir, a drug for chronic HCV infection, is metabolized mainly by the CYP3A4 enzyme, and genetic variants of this enzyme can affect the drug's plasma concentration and overall efficacy. Additionally, polymorphisms in the ABCB1 gene, which affects drug absorption and efflux, can also alter how effectively the drug is utilized, further influencing patient outcomes.